Table 3 Frequencies and percentages of participants’ response to potential DDIs
Drug–drug interaction pairs | No interaction | Used with monitoring | Contraindication | Not sure |
|---|---|---|---|---|
n (%) | n (%) | n (%) | n (%) | |
Acetaminophen/codeine and amoxicillin | 3395 (77.8) | 580 (13.3) | 167 (3.8) | 22 1 (5.1) |
Warfarin and sulfamethoxazole/trimethoprim | 403 (9.2) | 2432 (55.7) | 1241 (28.4) | 287 (66) |
Warfarin and digoxin | 2431 (55.7) | 887 (20.3) | 794 (18.2) | 251 (5.8) |
Digoxin and amiodarone | 353 (8.1) | 2240 (51.3) | 1434 (32.9) | 336 (7.7) |
Cyclosporine and rifampicin | 718 (16.5) | 2147 (49.2) | 1014 (23.2) | 484 (11.1) |
Digoxin and itraconazole | 447 (10.2) | 2552 (58.5) | 942 (21.6) | 422 (9.7) |
Digoxin and sildenafil | 2884 (66.1) | 457 (10.5) | 768 (17.6) | 254 (5.8) |
Simvastatin and itraconazole | 359 (8.2) | 716 (16.4) | 2906 (66.6) | 382 (8.8) |
Sildenafil and isosorbide mononitrate | 262 (6) | 363 (8.3) | 3438 (78.8) | 300 (6.9) |
Conjugated estrogens and raloxifene | 2224 (51) | 681 (15.6) | 760 (17.4) | 698 (16) |
Theophylline and ciprofloxacin | 522 (12) | 2119 (48.6) | 1339 (30.7) | 383 (8.8) |
Pimozide and ketoconazole | 371 (8.5) | 594 (13.6) | 2876 (65.9) | 522 (12) |
Warfarin and Fluconazole | 412 (9.4) | 2529 (58) | 1054 (24.2) | 368 (8.4) |
Alprazolam and itraconazole | 413 (9.5) | 326 (7.5) | 778 (17.8) | 2846 (65.2) |
Digoxin and clarithromycin | 404 (9.3) | 2502 (57.3) | 1087 (24.9) | 370 (8.5) |
warfarin and sulfinpyrazone | 443 (10.2) | 2519 (57.7) | 795 (18.2) | 606 (13.9) |
Dopamine and phenytoin | 567 (13) | 2388 (54.7) | 995 (22.8) | 413 (9.5) |
Fexofenadine HCL and metoprolol | 3025 (69.3) | 453 (10.4) | 349 (8) | 536 (12.3) |
Itraconazole and quinidine | 329 (7.5) | 620 (14.2) | 2916 (66.8) | 498 (11.4) |